Baidu
map

J Hypertens:接受治疗的顽固性高血压患者的神经认知

2019-03-02 xing.T 网络

由此可见,神经认知障碍在接受治疗的顽固性高血压成人中很常见,特别是对执行功能的检查。更好的神经认知与有氧适应性、微血管功能和CVRF独立相关。

中年高血压卒中风险增加和神经认知下降有关。然而,很少有研究评估治疗的抵抗性高血压患者的神经认知或治疗的顽固性高血压患者损害神经认知的潜在机制。

近日,高血压领域权威杂志Journal of Hypertension上发表了一篇研究文章,研究人员评估了96名超重成年患者神经认知障碍模式和潜在机制,这些成年人为治疗的顽固性高血压患者,年龄为41-81岁。使用由执行功能和记忆组成的45分钟系列测试评估神经认知功能。评估的血管和代谢机制包括脑血管危险因素(CVRFs:Framingham卒中风险概况)、胰岛素敏感性(稳态模型评估的胰岛素抵抗)、腰臀比、微血管功能(充血反应)和跑步机测试的运动时氧消耗峰值。简单的路径分析用于评估潜在的血管和代谢机制与神经认知之间的关联。

神经认知障碍较为常见,70%的样本在至少一个执行功能子测试中表现出受损,38%的样本至少存在一种记忆指标。更高水平的有氧适应性、更高的胰岛素敏感性和更好的微血管功能以及更低的CVRF和腰臀比与更好的神经认知相关。在路径分析中,有氧适应性、微血管功能和CVRF都与神经认知表现独立相关。胰岛素抵抗与执行功能较差有关,但老年参与者的记忆表现较好。

由此可见,神经认知障碍在接受治疗的顽固性高血压成人中很常见,特别是对执行功能的检查。更好的神经认知与有氧适应性、微血管功能和CVRF独立相关。

原始出处:

Smith, Patrick J.et al.Neurocognition in treatment-resistant hypertension profile and associations with cardiovascular biomarkers. Journal of Hypertension. 2019.https://journals.lww.com/jhypertension/Abstract/publishahead/Neurocognition_in_treatment_resistant.97257.aspx

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1727911, encodeId=dae21e27911b7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 29 17:43:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632892, encodeId=8fcd163289221, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sat Apr 06 08:43:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039031, encodeId=fba92039031b0, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Nov 27 07:43:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448271, encodeId=f91314482e171, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Mon Mar 04 09:43:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603520, encodeId=48571603520ec, content=<a href='/topic/show?id=ef43e455710' target=_blank style='color:#2F92EE;'>#神经认知#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74557, encryptionId=ef43e455710, topicName=神经认知)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e6519038657, createdName=szhvet, createdTime=Mon Mar 04 09:43:00 CST 2019, time=2019-03-04, status=1, ipAttribution=)]
    2019-06-29 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1727911, encodeId=dae21e27911b7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 29 17:43:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632892, encodeId=8fcd163289221, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sat Apr 06 08:43:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039031, encodeId=fba92039031b0, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Nov 27 07:43:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448271, encodeId=f91314482e171, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Mon Mar 04 09:43:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603520, encodeId=48571603520ec, content=<a href='/topic/show?id=ef43e455710' target=_blank style='color:#2F92EE;'>#神经认知#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74557, encryptionId=ef43e455710, topicName=神经认知)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e6519038657, createdName=szhvet, createdTime=Mon Mar 04 09:43:00 CST 2019, time=2019-03-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1727911, encodeId=dae21e27911b7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 29 17:43:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632892, encodeId=8fcd163289221, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sat Apr 06 08:43:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039031, encodeId=fba92039031b0, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Nov 27 07:43:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448271, encodeId=f91314482e171, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Mon Mar 04 09:43:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603520, encodeId=48571603520ec, content=<a href='/topic/show?id=ef43e455710' target=_blank style='color:#2F92EE;'>#神经认知#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74557, encryptionId=ef43e455710, topicName=神经认知)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e6519038657, createdName=szhvet, createdTime=Mon Mar 04 09:43:00 CST 2019, time=2019-03-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1727911, encodeId=dae21e27911b7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 29 17:43:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632892, encodeId=8fcd163289221, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sat Apr 06 08:43:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039031, encodeId=fba92039031b0, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Nov 27 07:43:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448271, encodeId=f91314482e171, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Mon Mar 04 09:43:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603520, encodeId=48571603520ec, content=<a href='/topic/show?id=ef43e455710' target=_blank style='color:#2F92EE;'>#神经认知#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74557, encryptionId=ef43e455710, topicName=神经认知)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e6519038657, createdName=szhvet, createdTime=Mon Mar 04 09:43:00 CST 2019, time=2019-03-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1727911, encodeId=dae21e27911b7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 29 17:43:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632892, encodeId=8fcd163289221, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Sat Apr 06 08:43:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039031, encodeId=fba92039031b0, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Nov 27 07:43:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448271, encodeId=f91314482e171, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Mon Mar 04 09:43:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603520, encodeId=48571603520ec, content=<a href='/topic/show?id=ef43e455710' target=_blank style='color:#2F92EE;'>#神经认知#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74557, encryptionId=ef43e455710, topicName=神经认知)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e6519038657, createdName=szhvet, createdTime=Mon Mar 04 09:43:00 CST 2019, time=2019-03-04, status=1, ipAttribution=)]

相关资讯

Brit J Cancer:膀胱癌中TYRO3可以作为生长抑制和细胞凋亡诱导的分子靶标

肌肉侵入性膀胱癌(MIBC)是一种恶性肿瘤并且预后差,并且缺乏有效的治疗靶标。在一些癌症类型中,致瘤依赖的TAM酪氨酸激酶受体家族成员(TYRO3, AXL, MERTK)已见报道,但是它们在膀胱癌中的角色仍旧不清楚。最近,有研究人员在2个人类膀胱肿瘤系列中评估了TAM受体的表达情况。研究发现,与正常的上皮相比,非MIBCs和MIBCs肿瘤中TYRO3表达量显著更高,但是AXL或者MERTK并没有

Am J Otolaryngol:在萎缩性鼻炎中局部丝裂霉素C使用能够协助碱性鼻洗利福平治疗

原发萎缩性鼻炎(PAR)是一种常见的古老疾病。最近,有研究人员调查了局部丝裂霉素C作为一种辅助药物对PAR患者主管和客观改善中的作用。研究是一个前瞻性的随机对照研究,在一个高级医院中进行,时间为2016年1月到2018年3月。研究包括了50名年龄在18岁到45岁的患有PAR的患者,并随机分成2组。2个小组分为对照组和丝裂霉素溶解于含有利福平碱性溶液碱洗组,对照组则只用含有利福平的碱性溶液碱洗。12

盘点:近期鼻炎与治疗盘点

【1】Medicine (Baltimore):针灸在过敏性鼻炎患者中的治疗效果研究https://www.ncbi.nlm.nih.gov/pubmed/30608427最近,有研究人员在舌下特异性过敏原免疫治疗(SASIT)的过敏性鼻炎(AR)患者中,回顾性的分析了针灸疗法作为一种附加的疗法(AAOT)对过敏性鼻炎患者的治疗效果。研究总共包括了120名符合研究标准的AR成年人患者。其中60

盘点:前列腺癌与治疗盘点

【1】Prostate Cancer P D:新系统性治疗对转移去势难治性前列腺癌患者总生存影响研究 https://www.nature.com/articles/s41391-018-0121-2#search-menu2004年,多烯紫杉醇展现出了能够延长转移去势难治性前列腺癌(mCRPC)患者总生存(OS)的效果。自从2010年,已经出现了5中系统性的治疗且能够延长mCRPC患者的OS

盘点:近期听力损失与治疗研究盘点

【1】Acta Otolaryngol:怀孕期间突发感官听力损失临床特性、治疗和结果研究https://www.ncbi.nlm.nih.gov/pubmed/30664387突发感官听力损失(SSNHL)在怀孕期间是可能发生的,但是概率很低,并且其中的机制很少了解。最近,有研究人员回顾性的分析了怀孕期间SSNHL发生的起因,并调查了临床特性、治疗情况和治疗结果。研究包括了30名怀孕期间SSN

Int J Impot Res:缺血性阴茎异常勃起治疗实践

阴茎分流非外科手术干预治疗缺血性阴茎勃起功能障碍(IPR)中是标准的医疗方法。由于阳痿率高、体纤维化和阴茎长度减少发生率高。最近的文献指出这些患者可以从直接的阴茎假体移植(PP)中受益。最近,有研究人员评估了当前IPR治疗的实践模式,并且调查了直接的PP移植在拖延较久的IPR(大于36小时)中的治疗效果。研究发现,调查的响应率为11.6%(n=251)。大多数的响应者为的泌尿科医师(173),来自

Baidu
map
Baidu
map
Baidu
map